PARKHOSPSHealthcare

Park Medi World Limited

Hospital · ISIN INE119201023 · BSE 544645 · NSE EQ · FV ₹2
Last price
₹278
+0.54%today
What this company does

Park Medi World Limited operates in Hospital, part of the Healthcare sector. It booked ₹476 cr of revenue in its latest quarter (Q1 FY27) and kept 17.3% of sales as profit.

63out of 100
Equitytale Health Score
Mixed

Healthier than 63% of companies in Healthcare, on the 5 of 6 measures we could read for it. Each measure is ranked against the 116–150 companies that reported it.

Measures financial condition, not whether to buy. Learn what this score means · How this is calculated

Price momentum
neutral
RSI (14)
47

At close. Not part of the score.

Profitability & returns70

How much profit it earns on the money it employs

Balance sheet60

How much it owes, and whether earnings cover the interest

Cash quality53

Whether reported profit actually arrives as cash

Valuation49

What today's price implies, against our models or its peers

Governance & risk88

How much of the promoters' stake is pledged, and how much they hold

Not measurable for this company: growth & consistency. Those pillars are left out of the score rather than counted as zero.

Is this company doing well?
not investment advice
Strengths
Makes a profit
Strong 17% net margin
Promoters hold 83%
No promoter shares pledged
Strong 16% return on equity
Watch-outs
None flagged from our data

What if I invest in PARKHOSPS?

Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.

You would put in
₹12.00 lakh
120 instalments
At 5% a year, it would become
₹15.50 lakh

The slider starts at 5%, taken from a generic assumption, not this company's history. That is history, not a forecast — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.

Key ratios · latest quarter + price
₹278 +0.54%
latest close · 2026-09-17
52-wk low ₹26742 sessions so far52-wk high ₹303
Is it cheap or expensive?
What you pay for the profits, book value and cash flow. Higher isn't automatically worse — it can signal faster growth.
P/E ratio33.9High
LowAverageHigh
P/B ratio5.94High
Below bookModerateHigh
EV / EBITDA22.4High
LowAverageHigh
How good is the business?
How much profit it earns from its money and its sales.
Return on equity16.3%Strong
WeakFairStrong ▸15%
Return on capital20.1%Strong
WeakFairStrong
Net margin17.3%Strong
ThinDecentStrong
EBITDA margin28.1%Healthy
ThinDecentHealthy
Is it financially safe?
How much it owes, and whether it can comfortably cover it.
Debt to equity0.11Comfortable
LowModerateHigh ▸1
Interest cover11.7×Strong
RiskyOkayStrong ▸5×
Current ratio2.06Ample
Tight ◂1HealthyAmple
More figures
Market cap
₹12,003 cr
Book value
₹47
EPS
₹2.05
latest quarter
Net debt
₹-9 cr
more cash than debt
Enterprise value
₹11,994 cr
EBITDA
₹535 cr
annualised
EBIT
₹460 cr
annualised
Operating margin
24.2%
Return on assets
11.7%
Earnings yield
2.95%
P/S
6.31
Sales / share
₹44.1
Tax rate
15.7%
Face value
₹2
Shares
43.2 cr
Working capital
₹559 cr
Current assets
₹1,088 cr
Current liabilities
₹529 cr
Delivery %
55.0%
Strong / safeFairWeak / riskyValuation — a level, not good/badBands are general rules of thumb, not advice.

P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-09-17.

Worth vs price · from the exchange filings
not investment advice
Hard to value confidentlyLow confidence
The market price is far above what these earnings- and book-based models support — a fast-growing or asset-light business can trade well above them for years, so we won't put a confident number on how overpriced it is.
Models span ₹51₹67, midpoint ₹59

An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.

P&L · Q1 FY27 (consolidated)
Revenue from Operations₹476 cr
Other Income₹8 cr
Total Income₹483 cr
Cost of Materials₹77 cr
Purchases of Stock-in-Trade₹0 cr
Inventory Change (±)₹-86.7 L
Employee Benefit Expense₹92 cr
Finance Costs₹10 cr
Depreciation & Amortisation₹19 cr
Other Expenses₹181 cr
Total Expenses₹378 cr
Profit before Tax₹105 cr
Tax Expense₹16 cr
Net Profit₹89 cr
Net margin on total income18.3%
Where the money goes · Q1 FY27
% of total income
Materials + stock-in-trade₹76 cr15.8%
Employee benefit expense₹92 cr19.1%
Finance costs₹10 cr2.0%
Depreciation & amortisation₹19 cr3.9%
Other expenses₹181 cr37.4%
Tax expense₹16 cr3.4%
Profit for the period₹89 cr18.3%
Total income ₹483 cradds up to ₹100 ✓
Quarterly results · consolidated (₹ cr)
MetricQ3 FY26Q4 FY26Q1 FY27
Revenue410 cr460 cr476 cr
Total income419 cr468 cr483 cr
Expenses341 cr365 cr378 cr
Profit before tax78 cr103 cr105 cr
Tax25 cr27 cr16 cr
Net profit (owners' share)51 cr71 cr83 cr
Net margin (owners' share, on revenue)12.4%15.4%17.3%
EPS (₹)1.351.782.05
Balance sheet & cash flow · as of Mar 2026
Low debt
Total assets
₹2,813 cr
Shareholder equity
₹2,022 cr
parent shareholders
Total debt
₹228 cr
Cash
₹237 cr
Peer comparison
Hospital · by market value
CompanyPriceMarket capP/E
Apollo Hospitals Enterprise Limited₹8,769₹1.26 L cr54.3
Max Healthcare Institute Limited₹1,037₹1.01 L cr78.1
Manipal Health Enterprises Limited₹722₹85,125 cr92.0
Fortis Healthcare Limited₹886₹66,897 cr62.8
Aster DM Quality Care Limited₹761₹39,412 cr613.4
Global Health Limited₹1,424₹38,273 cr60.2
Narayana Hrudayalaya Ltd.₹1,869₹38,187 cr45.8
Krishna Institute of Medical Sciences Limited₹792₹33,258 cr190.3
Dr. Agarwal's Health Care Limited₹500₹15,855 cr87.4
Same industry · latest reported numbers · not a recommendation.
Who owns it · 2026-06-30
No pledge
Promoter
82.9%
FII / Foreign
0.8%
DII / Domestic
8.9%
Retail / others
7.3%
Smart-money activity
Bulk / block deals
short · NSE9,50015 Sep 26
short · NSE50010 Aug 26
short · NSE123 Jul 26
Stake changes
BoughtKotak Mahindra Mutual Fund→ 5.04% · 1.75 L11 Mar 26
What shareholders were asked to approve

A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.

Postal ballot · 3 Sep 2026
See the official result
1
Amending certain objects of Initial Public Offer (“IPO”) proceeds
Backed by 100% of shareholders other than promotersneeded 75%
3.71 cr votes for, 3,919 against · 0% of mutual funds and other big investors said no

Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.

Who controls this company, and what it pays them

Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.

The promoter group — 22 named members
owning 82.9% between them · as of 2026-06-30
AJIT GUPTA74.59%
ANKIT GUPTA8.31%
ABHISHEK AGGARWALno shares
ADITYA GUPTAno shares
Ajisha Infra Private Limitedno shares
AJIT GUPTA HUFno shares
APOORVA GUPTAno shares
BINA GUPTAno shares

Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.

Money it raised, and what it did with it

When a company raises money from investors, it has to say up front what the money is for. The rules then make it report, every three months until the money is gone, how much of each of those things it has actually paid for — so a promise made while asking for the money can be checked afterwards.

₹770 cr raised in Dec 2025 by selling shares to the public

As of Jun 2026, the company says it has spent 91% of what it set aside, leaving ₹65 cr still to be spent. Crisil Rating Limited watches the spending on the exchange’s behalf.

Repayment/ prepayment, in full or in part, of outstanding borrowings availed by our Company and our Subsidiaries
100%
₹380 cr of ₹380 cr
Funding capital expenditure for development of new hospital by our Subsidiary Park Medicity (NCR) Private Limited
32%
₹20 cr of ₹61 cr
Funding capital expenditure for purchase of medical equipment by our Company and our Subsidiaries, Blue Heavens Healthcare Private Limited and Ratangiri Innovations Private Limited
13%
₹4 cr of ₹27 cr
Unidentified inorganic acquisitions and general corporate purposes
100%
₹245 cr of ₹245 cr

Every figure above is taken from the statement the company files with the stock exchange each quarter, for as long as money it has raised remains unspent. The only thing we work out is how much of each stated purpose has been paid for — one number divided by another from the same filing. Whether a plan that changed was a good change is not something a filing can tell you. See the filing

How the stock has moved · adjusted for splits & bonuses
Data from primary exchange filings · analysis tool, not investment advice.